• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
187468 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
& `* {6 h! O3 h" h) |$ ~7 I# s* f) O1 y0 m

1 ?! M" p2 j- m3 F& U! F# PSub-category:
) B& \+ c' ^3 o# zMolecular Targets ; S' u8 X& Y8 D8 [* L0 j6 M. I
7 a" s7 Q% B2 Z, [$ E4 z
- |! v/ F5 Q) f
Category:
2 f9 n+ Y% M0 M; eTumor Biology
* Y* Q/ S; v3 O8 n+ D
: U# q8 P3 L( `8 a9 J, a* a  C3 g$ F" V. Z: ^. P1 e$ s
Meeting:
6 h, ~; C, j& u2011 ASCO Annual Meeting
. N+ G0 \# C' \' b* u8 U: |
( K' t" ]" }% e" F, z' j* ^2 _8 Q# j) S  d) B1 C
Session Type and Session Title:$ l9 l6 V2 u7 R, v
Poster Discussion Session, Tumor Biology
5 d  D8 [  {# {1 a2 c7 c# \8 M! H- D4 U

& g* c9 [- l0 a( bAbstract No:7 w$ ^; }' ]) |& V& z
10517
; C8 @* O5 ]' G1 a) e8 _, ~
9 |$ h, F' i1 x( i% L& y) u% `  l: W! f4 o6 b# \# ?+ ?
Citation:6 Y9 W3 d2 r& ~6 e, x+ D# v0 t
J Clin Oncol 29: 2011 (suppl; abstr 10517) ( l! S5 |0 c; ?) W2 G& a
5 a7 _3 s& C" \

5 k  W$ ?/ r( ~( ]Author(s):2 i! ?- i- V& b) F# x8 o
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
: O& A# S4 z. q+ ?8 K0 S5 U8 g* K
, Z. }' T4 s1 C9 \/ N0 L! G- X" t3 y% \" _- c7 P

, j; ]# O% p" s4 sAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.+ z3 p; o0 h( }( H1 E8 [

1 o5 L& R; L) x/ u+ a+ bAbstract Disclosures1 X' k! J7 I/ P$ ~2 A+ n. E

7 k4 [# _$ w6 @Abstract:* w7 W0 `& L- O% ?8 P0 ]* k1 z/ d& H
! w7 W, d$ F+ k/ E
/ Y/ Y, g& V- J. w# Y
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
0 A! U" n) |% x1 N& _( B  q1 p7 E9 V4 z/ r& E' A  X

3 t6 R; C- K! B2 A
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 5 l! j" R# c; z& Y; r% }
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
0 n  U; W( ]7 Z9 R  L3 E+ w
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
5 n. `5 o7 u" I$ J! |易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
) X" c6 _, X$ q( H6 t+ S  |, VALK一个指标医院要900多 ...
  Y* ?: b) d- {6 s7 p) ~
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?8 J2 s3 v7 S3 b6 g# j% j: j4 _

. @# b+ x) m$ E; n$ Z1 a" `$ D现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表